Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D 2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers

Journal of Clinical Pharmacology

Volumn 50, Issue 11, 2010, Pages 1273-1279

  Luo, Wen Lin ^a   Crumley, Tami ^a   Ebel, David ^a   Atiee, George J ^b   Royalty, Jane ^c   Johnson Levonas, Amy O ^a   Wagner, John ^a   Lai, Eseng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Healthcare Discoveries Inc   (United States)

^c D/b/a Covance GFI Research   (United States)

Author keywords

ECG; Laropiprant; QTc interval; thorough QT

Indexed keywords

LAROPIPRANT; MOXIFLOXACIN; PLACEBO; PROSTAGLANDIN D2;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; AZA COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INDOLES; LONG QT SYNDROME; MALE; MIDDLE AGED; QUINOLINES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; YOUNG ADULT;

EID: 78449267073     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009360042     Document Type: Article

References (17)

1. Carlson LA Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005 ; 258: 94-114.
2. Capuzzi DM, Morgan JM, Brusco OA Jr, Intenzo CM Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep. 2000 ; 2: 64-71.
3. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med. 2004 ; 62: 229-234.
4. Morgan JM, Capuzzi DM, Guyton JR A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998 ; 82: 29U-34U.
5. Mills E., Prousky J., Raskin G., et al. The safety of over-the-counter niacin: a randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol. 2003 ; 3: 4.
6. Morrow JD, Parsons WG III, Roberts LJ Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989 ; 38: 263-274.
7. Morrow JD, Awad JA, Oates JA, Roberts LJ Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992 ; 98: 812-815.
8. Phillips WS, Lightman SL Is cutaneous flushing prostaglandin mediated ? Lancet. 1981 ; 1: 754-756.
9. Wilkin JK, Fortner G., Reinhardt LA, Flowers OV, Kilpatrick SJ, Streeter WC Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther. 1985 ; 38: 273-277.
10. Maciejewski-Lenoir D., Richman JG, Hakak Y., Gaidarov I., Behan DP, Connolly DT Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006 ; 126: 2637-2646.
11. Cheng K., Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006 ; 103: 6682-6687.
12. Benyo Z., Gille A., Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol. 2006 ; 70: 1844-1849.
13. Paolini JF, Mitchel YB, Reyes R., et al. Effects of laropiprant on nicotinic Acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 ; 101: 625-630.
14. European Medicines Agency. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs: E14. Geneva, Switzerland; 2005. http://www.ich.org/LOB/media/MEDIA1476.pdf. Accessed September 30, 2009.
15. Iwamoto M., Kost JT, Mistry GC, et al. Raltegravir thorough QT/ QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008 ; 48: 726-733.
16. Lai E., Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther. 2008 ; 83: 840-847.
17. Karanam B., Madeira M., Bradley S., et al. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. Drug Metab Dispos. 2007 ; 35: 1196-1202.